Literature DB >> 8730750

Regulation of tumour necrosis factor production by adrenal hormones in vivo: insights into the antiinflammatory activity of rolipram.

E R Pettipher1, J M Labasi, E D Salter, E J Stam, J B Cheng, R J Griffiths.   

Abstract

1. The role of adrenal hormones in the regulation of the systemic and local production of tumour necrosis factor (TNF alpha) was examined in male Balb/c mice. 2. Intraperitoneal injection of 0.3 mg E. coli lipopolysaccharide (LPS, 0111:B4) led to high levels of circulating TNF alpha without stimulating TNF alpha production in the peritoneal cavity. Systemic production of TNF alpha in response to LPS was increased in adrenalectomized animals and in normal animals treated with the beta-adrenoceptor antagonist, propranolol. The glucocorticoid antagonist, RU 486, did not modify systemic TNF alpha production. These results indicate that systemic TNF alpha production is regulated by adrenaline but not by corticosterone. 3. When mice were primed with thioglycollate, TNF alpha was produced in the peritoneal cavity in response to low dose LPS (1 micrograms). The levels of TNF alpha in the peritoneal cavity were not enhanced by adrenalectomy or by treatment with either propranolol or RU 486, indicating local production of TNF alpha in the peritoneal cavity is not regulated by adrenaline or corticosterone. 4. The phosphodiesterase type IV (PDE-IV) inhibitor, rolipram, inhibited both the systemic production of TNF alpha in response to high dose endotoxin (ED50 = 1.3 mg kg-1) and the local production of TNF alpha in the peritoneal cavity in response to low dose endotoxin (ED50 = 9.1 mg kg-1). In adrenalectomized mice there was a slight reduction in the ability of rolipram to inhibit the systemic production of TNF alpha (ED50 = 3.3 mg kg-1) while the ability of rolipram to inhibit the local production of TNF alpha in the peritoneal cavity was virtually abolished (24% inhibition at 30 mg kg-1). The glucocorticoid antagonist, RU 486, also reduced the ability of rolipram to inhibit local TNF alpha production while propranolol was without effect. 5. Systemic treatment with rolipram increased the plasma concentrations of corticosterone in normal mice but not in adrenalectomized mice indicating that rolipram can cause adrenal stimulation in vivo. 6. In summary, these data indicate that systemic production of TNF alpha in response to high dose endotoxin is controlled differently from the local production of TNF alpha in response to low dose endotoxin. The systemic production of TNF alpha is regulated by catecholamines, but not by corticosterone, while the local production of TNF alpha in the peritoneal cavity is not regulated by basal levels of either catecholamines or corticosterone. 7. These data also show that the ability of rolipram to inhibit the local production of TNF alpha is dependent on the release of corticosterone from the adrenal glands.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8730750      PMCID: PMC1909448          DOI: 10.1111/j.1476-5381.1996.tb15317.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  23 in total

Review 1.  Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors.

Authors:  J A Beavo; D H Reifsnyder
Journal:  Trends Pharmacol Sci       Date:  1990-04       Impact factor: 14.819

2.  Reversal of the anti-inflammatory effects of dexamethasone by the glucocorticoid antagonist RU 38486.

Authors:  S H Peers; D Moon; R J Flower
Journal:  Biochem Pharmacol       Date:  1988-02-01       Impact factor: 5.858

3.  A comparison of the acute inflammatory response in adrenalectomised and sham-operated rats.

Authors:  R J Flower; L Parente; P Persico; J A Salmon
Journal:  Br J Pharmacol       Date:  1986-01       Impact factor: 8.739

4.  Differential regulation of IL 6, IL 1 A, IL 1 beta and TNF alpha production in LPS-stimulated human monocytes: role of cyclic AMP.

Authors:  S Bailly; B Ferrua; M Fay; M A Gougerot-Pocidalo
Journal:  Cytokine       Date:  1990-05       Impact factor: 3.861

5.  The effect of adrenalectomy on interleukin-1 release in vitro and in vivo.

Authors:  M Perretti; C Becherucci; G Scapigliati; L Parente
Journal:  Br J Pharmacol       Date:  1989-12       Impact factor: 8.739

6.  Influence of endogenous glucocorticoid on endotoxin-induced production of circulating TNF-alpha.

Authors:  M Parant; C Le Contel; F Parant; L Chedid
Journal:  Lymphokine Cytokine Res       Date:  1991-08

7.  Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosan-stimulated respiratory burst by 'type IV'-selective PDE inhibitors.

Authors:  G Dent; M A Giembycz; K F Rabe; P J Barnes
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

8.  Preliminary identification and role of phosphodiesterase isozymes in human basophils.

Authors:  P T Peachell; B J Undem; R P Schleimer; D W MacGlashan; L M Lichtenstein; L B Cieslinski; T J Torphy
Journal:  J Immunol       Date:  1992-04-15       Impact factor: 5.422

9.  Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst.

Authors:  C P Nielson; R E Vestal; R J Sturm; R Heaslip
Journal:  J Allergy Clin Immunol       Date:  1990-11       Impact factor: 10.793

10.  Neuroendocrine regulation of in vivo cytokine production and effects: I. In vivo regulatory networks involving the neuroendocrine system, interleukin-1 and tumor necrosis factor-alpha.

Authors:  L D Butler; N K Layman; P E Riedl; R L Cain; J Shellhaas; G F Evans; S H Zuckerman
Journal:  J Neuroimmunol       Date:  1989-09       Impact factor: 3.478

View more
  6 in total

1.  Inhibitory effects of cyclic AMP elevating agents on lipopolysaccharide (LPS)-induced microvascular permeability change in mouse skin.

Authors:  K Irie; E Fujii; H Ishida; K Wada; T Suganuma; T Nishikori; T Yoshioka; T Muraki
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

2.  Low-level laser therapy (LLLT) acts as cAMP-elevating agent in acute respiratory distress syndrome.

Authors:  Flávia Mafra de Lima; Leonardo M Moreira; A B Villaverde; Regiane Albertini; Hugo C Castro-Faria-Neto; Flávio Aimbire
Journal:  Lasers Med Sci       Date:  2010-12-24       Impact factor: 3.161

3.  Role of p38 MAP kinase in LPS-induced airway inflammation in the rat.

Authors:  E B Haddad; M Birrell; K McCluskie; A Ling; S E Webber; M L Foster; M G Belvisi
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

4.  Inhibition of pulmonary eosinophilia and airway hyperresponsiveness in allergic mice by rolipram: involvement of endogenously released corticosterone and catecholamines.

Authors:  T T Kung; Y Crawley; B Luo; S Young; W Kreutner; R W Chapman
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

5.  Novel synthetic biscoumarins target tumor necrosis factor-α in hepatocellular carcinoma in vitro and in vivo.

Authors:  Hosadurga Kumar Keerthy; Chakrabhavi Dhananjaya Mohan; Kodappully Sivaraman Siveen; Julian E Fuchs; Shobith Rangappa; Mahalingam S Sundaram; Feng Li; Kesturu S Girish; Gautam Sethi; Andreas Bender; Kanchugarakoppal Subbegowda Rangappa
Journal:  J Biol Chem       Date:  2014-09-17       Impact factor: 5.157

Review 6.  Neural immune pathways and their connection to inflammatory diseases.

Authors:  Farideh Eskandari; Jeanette I Webster; Esther M Sternberg
Journal:  Arthritis Res Ther       Date:  2003-09-23       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.